nav.banner_textnav.banner_cta →
SwissNova Labs
Semaglutide 10mg research vial
SwissNova Labs
Semaglutide 10mg · 10mg
≥99% Purity · COA Included
Metabolic

Semaglutide 10mg

Purity: 99%+
Size: 10mg
Grade: Research
Form: Lyophilized
✦
SwissNova Labs · Research Grade
Back to catalog
MetabolicNEW!

Semaglutide 10mg

High-dose GLP-1 receptor agonist for advanced metabolic research.

Weight reduction — 15–20% body weight loss demonstrated in clinical trialsGlycemic control — potent insulin secretagogue with glucagon suppressionCardiovascular protection — 26% reduction in MACE in SUSTAIN-6 trialAppetite suppression — central CNS action reduces caloric intake
$120.00
10mg · Research use only
Compound Specifications
Purity99%+
Molecular Weight4113.6 Da
Vial Size10mg
SequenceHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg
Dosage Reference
Range0.25–2.4 mg
FrequencyOnce weekly
RouteSubcutaneous injection
Half-life~7 days
Vial Supply
Duration~10 weeks supply
Week 1Week 10

1 mg/week titration protocol

Why Researchers Choose This Compound

Key Benefits

01
Weight reduction

15–20% body weight loss demonstrated in clinical trials

02
Glycemic control

potent insulin secretagogue with glucagon suppression

03
Cardiovascular protection

26% reduction in MACE in SUSTAIN-6 trial

04
Appetite suppression

central CNS action reduces caloric intake

Administration Guide

Recommended Injection Sites

Optimal injection locations for Semaglutide 10mg based on its route (Subcutaneous injection) and pharmacokinetic profile.

Tap a glowing zone on the body map to highlight the matching site card — or tap a card to activate the zone.

Site Map — front

Tap a zone to inject

Best
Good
Acceptable
Primary Sites
Abdomen
Best
Periumbilical fat

Preferred site for weekly GLP-1 injections.

Thigh
Good
Anterolateral mid-thigh

Good alternative for weekly dosing.

Secondary Sites
Deltoid
Acceptable
Lateral shoulder fat

Use if other sites unavailable.

Needle Specs
Gauge27–29 gauge
Length5/16" – 1/2"
Angle45–90°
Site Rotation

Rotate weekly injection sites.

Avoid
  • IV administration
  • Intramuscular injection
Mechanism of Action

Active Signaling Pathway

Synergistic Protocols

Recommended Stacks

Semaglutide 10mg is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.

Fitness & Performance

Metabolic Reset Protocol

Next-generation GLP-1 + amylin combination for advanced weight management research.

NEW!
Semaglutide 10mg — Primary — GLP-1 receptor agonist
Activates GLP-1 receptors to suppress appetite, slow gastric emptying, and improve glycemic control. 15–20% body weight reduction in clinical trials.
20–52 weeksAdvanced3 compounds
View Full Stack →
Supply Calculator

How long will one vial last?

Based on standard research protocols, here's exactly what to expect from a single 10mg vial — and when to plan your next order.

One vial lasts
10
weeks
That's approximately 2 months of continuous use at the standard protocol dose.
Reorder around week 9 to avoid running out
Your supply timeline10mg vial
Start↑ ReorderWeek 10 — empty
1
2
3
4
5
6
7
8
9
10
Active supplyReorder week
How we calculated this
10mg vial ÷ 1 mg/week titration protocol = 10 weeks of supply

Actual duration may vary based on your specific protocol. Always consult your research guidelines for precise dosing schedules.

Research Literature

Scientific Background

Mechanism of Action

Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native GLP-1. Its C18 fatty acid chain enables albumin binding, extending half-life to ~7 days. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite.

Clinical Context

Semaglutide represents the current gold standard in GLP-1 receptor agonist research. The 10mg vial format supports extended research protocols or multi-subject studies.

Research Highlights

  • SUSTAIN and STEP clinical trial programs demonstrated 15–20% body weight reduction
  • Shown to reduce major adverse cardiovascular events (MACE) by 26% in SUSTAIN-6
  • FDA-approved for type 2 diabetes (Ozempic) and obesity (Wegovy)
  • Demonstrated neuroprotective effects in Parkinson's disease research

Storage & Reconstitution

PROTOCOL NOTE

Titrate dose over 16–20 weeks. Typical research protocol: 20–52 weeks.

RESEARCH USE ONLY:All products are sold strictly for in vitro research and laboratory use. Not intended for human consumption, clinical use, diagnosis, treatment, or prevention of any disease or condition. By purchasing, you confirm you are a qualified researcher and will use these compounds in accordance with all applicable laws and regulations.